Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $23,800.00 in Stock

Posted by Mitch Edgeman on Feb 15th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $11.90, for a total transaction of $23,800.00. Following the completion of the sale, the president now directly owns 2,877,138 shares of the company’s stock, valued at $34,237,942.20. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Songjiang Ma also recently made the following trade(s):

On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total transaction of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total value of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total value of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total value of $9,560.56.

Gyre Therapeutics Stock Performance

Shares of GYRE opened at $11.98 on Friday. The business’s fifty day moving average price is $11.20 and its 200 day moving average price is $12.32. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $26.37.

Hedge Funds Weigh In On Gyre Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its stake in Gyre Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock worth $1,251,000 after purchasing an additional 8,624 shares during the last quarter. Barclays PLC lifted its stake in Gyre Therapeutics by 13.5% during the fourth quarter. Barclays PLC now owns 10,543 shares of the company’s stock worth $128,000 after purchasing an additional 1,255 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after purchasing an additional 913 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock valued at $1,386,000 after buying an additional 918 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Gyre Therapeutics in the fourth quarter valued at $1,225,000. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.